The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model

Oncotarget

Volumn 5, Issue 1, 2014, Pages 103-107

  Kobold, Sebastian ^a   Merk, Melanie ^a   Hofer, Luisa ^a   Peters, Philip ^a   Bucala, Richard ^b   Endres, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cancer; Cytokine; MIF

Indexed keywords

DOPACHROME TAUTOMERASE; IMMUNOGLOBULIN G ANTIBODY; SMALL INTERFERING RNA; DOPACHROME ISOMERASE; ISOMERASE; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME BLOOD LEVEL; ENZYME RELEASE; ENZYME SYNTHESIS; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL LINE; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE, TUMOR; FEMALE; GENE KNOCKDOWN TECHNIQUES; INTRAMOLECULAR OXIDOREDUCTASES; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR TARGETED THERAPY; RNA, SMALL INTERFERING;

EID: 84893875203     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1560     Document Type: Article

References (14)

1. Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 2007;26(3):281-5.
2. Merk M, Mitchell RA, Endres S, Bucala R. D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. Cytokine. 2012;59(1):10-7.
3. Odh G, Hindemith A, Rosengren AM, Rosengren E, Rorsman H. Isolation of a new tautomerase monitored by the conversion of D-dopachrome to 5,6-dihydroxyindole. Biochem Biophys Res Commun. 1993;197(2):619-24.
4. Merk M, Zierow S, Leng L, Das R, Du X, Schulte W, Fan J, Lue H, Chen Y, Xiong H, Chagnon F, Bernhagen J, et al. The D-dopachrome tautomerase (DDT) gene product is a cytokine and functional homolog of macrophage migration inhibitory factor (MIF). Proceedings of the National Academy of Sciences of the United States of America. 2011;108(34):E577-85.
5. Coleman AM, Rendon BE, Zhao M, Qian MW, Bucala R, Xin D, Mitchell RA. Cooperative regulation of non-small cell lung carcinoma angiogenic potential by macrophage migration inhibitory factor and its homolog, D-dopachrome tautomerase. J Immunol. 2008;181(4):2330-7.
6. Xin D, Rendon BE, Zhao M, Winner M, McGhee Coleman A, Mitchell RA. The MIF homologue D-dopachrome tautomerase promotes COX-2 expression through beta-catenin-dependent and -independent mechanisms. Mol Cancer Res. 2010;8(12):1601-9.
7. Choi S, Kim HR, Leng L, Kang I, Jorgensen WL, Cho CS, Bucala R, Kim WU. Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice. J Immunol. 2012;189(8):3905-13.
8. Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res. 2005;11(3):1050-8.
9. Denz A, Pilarsky C, Muth D, Ruckert F, Saeger HD, Grutzmann R. Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J Surg Res. 2010;160(1):29-34.
10. Yaddanapudi K, Putty K, Rendon BE, Lamont GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW, Mitchell RA. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol. 2013;190(6):2984-93.
11. Hussain F, Freissmuth M, Volkel D, Thiele M, Douillard P, Antoine G, Thurner P, Ehrlich H, Schwarz HP, Scheiflinger F, Kerschbaumer RJ. Human Anti-Macrophage Migration Inhibitory Factor (MIF) Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo. Mol Cancer Ther. 2013.
12. DuPre SA, Redelman D, Hunter KW, Jr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol. 2007;88(5):351-60.
13. Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufmann A, Düwell P, Lindner M, Koch I, Heidegger S, Rothenfußer S, Schnurr M, Huber RM, Wilczak W, Endres S. Interleukin-22 is frequently expressed in lung cancer and may contribute to tumor progression in chemotherapy-resistant disease. J Thorac Oncol. 2013 Aug;8(8):1032-42.
14. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Kroger N. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010;95(5):785-93.